- ABOUT ME
- AREAS OF FOCUS
- EDUCATION & LEADERSHIP
- LOCATIONS & HOSPITALS
- NEWS & PUBLICATIONS
Dr. Au was drawn to urology in medical school when he recognized it as a field known for implementing cutting-edge science and technology to further the care of patients as well as being a field centered around quality-of-life issues. Dr. Au loves that as a surgeon, he can follow in this tradition and both deliver tangible solutions to his patients and maintain a continuity of care unique within surgical specialties.
Dr. Au specializes in benign prostatic hyperplasia (BPH) treatments and has advanced training in the latest techniques, including Holmium Laser Enucleation of the Prostate (HoLEP). He also has experience in minimally invasive and robotic surgery for benign and oncologic urologic conditions. He received his training at the University of Kansas, which is known for extensive training in urologic oncology, robotic surgery, and advanced laser BPH and stone surgery.
Dr. Au loves the outdoors and the many options that living in the Portland metro area affords to appreciate the natural beauty of the Pacific Northwest. Outside of work, Dr. Au enjoys cooking, travelling, photography, baseball, and exploring the mountains and forests of the Pacific Northwest.
Member, American Urological Association
EDUCATION & TRAINING
Residency, University of Kansas Medical Center, Kansas City, KS, 2022
MD, Saint Louis University School of Medicine, Saint Louis, MO, 2017
BA, University of California Los Angeles, Los Angeles, CA, 2009
Urology – Board Eligible
Au D, Lee E, Popoola T, et al. Factors Associated with Utilization of Neoadjuvant Chemotherapy in Charlson Comorbidity Zero Non-Metastatic Muscle-Invasive Bladder Cancer Patients. International Brazilian Journal of Urology. Vol 47. No 4:803-818. July/Aug 2021.
May D, Smelser W, Au D, Holzbeierlein J. AUA Update Series Lesson on The Incidental Adrenal Mass: Diagnosis and Treatment. March 2021.
May A, Henke J, Au D, et al. National trends in the Utilization of Androgen Deprivation Therapy for Very Low Risk Prostate Cancer. Urology. Vol 130:79-85. August 2019.